Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR-1819 in Healthy Subjects
NCT04561128Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) and asthma comparing SHR-1819 with Placebo (2 arms). Primary endpoint: Adverse events at 13 weeks. Started Nov 2020; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT04561128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561128.